Baird Maintains Outperform on Ocular Therapeutix, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy maintains an Outperform rating on Ocular Therapeutix (NASDAQ:OCUL) but lowers the price target from $18 to $17.
August 08, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Baird analyst Colleen Kusy maintains an Outperform rating on Ocular Therapeutix but lowers the price target from $18 to $17.
The Outperform rating suggests continued confidence in the company's performance, but the lowered price target indicates a slight reduction in expected upside. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100